Alfred Sandrock Net Worth

The estimated Net Worth of Alfred Sandrock is at least $80.4 Million dollars as of 2 April 2024. Mr. Sandrock owns over 12,115 units of Biogen Inc stock worth over $64,274,017 and over the last 11 years he sold BIIB stock worth over $10,781,561. In addition, he makes $5,312,560 as Executive Vice President, Research and Development, and Chief Medical Officer at Biogen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Sandrock BIIB stock SEC Form 4 insiders trading

Alfred has made over 43 trades of the Biogen Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 12,115 units of BIIB stock worth $119,454 on 2 April 2024.

The largest trade he's ever made was exercising 15,030 units of Biogen Inc stock on 22 October 2013 worth over $910,217. On average, Alfred trades about 2,237 units every 66 days since 2013. As of 2 April 2024 he still owns at least 322,839 units of Biogen Inc stock.

You can see the complete history of Mr. Sandrock stock trades at the bottom of the page.

Alfred Sandrock biography

Dr. Alfred W. Sandrock, Jr. M.D. Ph.D. is Executive Vice President, Research and Development, Chief Medical Officer of Biogen Inc. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc. (Merck), a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payors and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company.

What is the salary of Alfred Sandrock?

As the Executive Vice President, Research and Development, and Chief Medical Officer of Biogen Inc, the total compensation of Alfred Sandrock at Biogen Inc is $5,312,560. There are 2 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.

How old is Alfred Sandrock?

Alfred Sandrock is 62, he's been the Executive Vice President, Research and Development, and Chief Medical Officer of Biogen Inc since 2019. There are 9 older and 15 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.

What's Alfred Sandrock's mailing address?

Alfred's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Biogen Inc

Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.

What does Biogen Inc do?

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Complete history of Mr. Sandrock stock trades at Biogen Inc, Neurocrine Biosciences, and Voyager Therapeutics Inc

Biogen Inc executives and stock owners

Biogen Inc executives and other stock owners filed with the SEC include:

• Michel Vounatsos,
  Chief Executive Officer, Director
• Susan Alexander,
  Executive Vice President, Chief Legal Officer and Secretary
• Alfred Sandrock,
  Executive Vice President, Research and Development, Chief Medical Officer
• Chirfi Guindo,
  Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
• Michel Vounatsos,
  CEO & Director
• Susan H. Alexander Esq.,
  Exec. VP, Chief Legal Officer & Sec.
• Susan H. Alexander,
  Exec. VP, Chief Legal Officer & Sec.
• Michael R. McDonnell,
  Exec. VP & CFO
• Chirfi Guindo,
  Exec. VP of Global Product Strategy & Commercialization
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Robert Pangia,
  Independent Director
• Brian Posner,
  Independent Director
• Alexander Denner,
  Independent Director
• Nancy Leaming,
  Independent Director
• Caroline Dorsa,
  Independent Director
• Stephen Sherwin,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Richard Mulligan,
  Independent Director
• Jesus Mantas,
  Independent Director
• William Hawkins,
  Independent Director
• Robin Kramer,
  Chief Accounting Officer, Vice President
• Daniel Karp,
  Executive Vice President, Corporate Development
• Alphonse Galdes,
  Executive Vice President, Pharmaceutical Operations and Technology
• Ginger Gregory,
  Chief Human Resource Officer, Executive Vice President
• Michael McDonnell,
  Chief Financial Officer, Executive Vice President
• Dr. Sanjay Jariwala,
  Sr. VP of Worldwide Medical
• Nicole Murphy,
  Head of Pharmaceutical Operations & Technology
• Dr. Anabella Villalobos Ph.D.,
  Sr. VP of Biotherapeutic & Medicinal Sciences
• Dr. Alphonse Galdes,
  Exec. VP of Pharmaceutical Operations & Technology
• Dr. Ginger Gregory,
  Exec. VP & Chief HR Officer
• Natacha Gassenbach,
  Chief Communication Officer & Head of Corp. Affairs
• Michael Hencke,
  Director of Investor Relations
• Mark J. Hernon,
  Sr. VP & Chief Information Officer
• Robin C. Kramer,
  Sr. VP & Chief Accounting Officer
• George A Scangos,
  Chief Executive Officer
• Adriana Karaboutis,
  EVP, Tech. and Bus. Solutions
• Michael D Ehlers,
  EVP, Research and Development
• Gregory F Covino,
  VP, Chief Accounting Officer
• Lynn Schenk,
  Director
• Paul Mc Kenzie,
  EVP Pharmaceutical Oper & Tech
• Paul J Clancy,
  CFO
• Kenneth Di Pietro,
  EVP Human Resources
• Adam Koppel,
  SVP, Chief Strategy Officer
• Susan Langer,
  Director
• Jean Paul Kress,
  EVP Pres Int'l & Global Hd GTO
• Priya Singhal,
  Head of Development
• Jeffrey D Capello,
  EVP & Chief Financial Officer
• Monish D Patolawala,
  Director
• Phillip A Sharp,
  Director
• Steven H Holtzman,
  EVP Corp Devel and Strategy
• John Cox,
  EVP Pharmaceutical Oper & Tech
• Spyridon Artavanis Tsakonas,
  SVP, Chief Scientific Officer
• William Young,
  Director
• Raymond Pawlicki,
  SVP, Chief Information Officer
• Stuart A Kingsley,
  EVP, Global Comm. Operations
• Douglas E Williams,
  EVP Research & Development
• Craig Eric Schneier,
  EVP, Human Resources
• Robert E. Gagnon,
  Chief Acct Officer VP & Contr
• Francesco Granata,
  EVP Global Commercial Operatio
• James C Mullen,
  CEO and President
• Michael F Mac Lean,
  SVP, Chief Accounting Officer
• Bruce Ross,
  Director
• Robert A Hamm,
  SVP, Immunology Business Unit
• Cecil B Pickett,
  President, R & D
• Marijn E Dekkers,
  Director
• Lawrence C Best,
  Director
• Faheem Hasnain,
  SVP, Oncology SBU
• Hans Peter Hasler,
  SVP, International
• Mark C Wiggins,
  EVP - Business Development
• Michael Lytton,
  EVP Corporate & Business Devel
• Alan Glassberg,
  Director
• John Michael Dunn,
  EVP - New Ventures
• Michael Gilman,
  EVP - Research
• Thomas J Bucknum,
  EVP. General Counsel, Sec.
• Nabil Hanna,
  EVP, Research
• William H Rastetter,
  Executive Chairman
• William R Rohn,
  Exec VP & COO
• Sylvie L Gregoire,
  EVP, Bus. Dev & Program Mgmt.
• Burt A Adelman,
  EVP, Development
• Alan Belzer,
  Director
• Michael Kowolenko,
  SVP, Pharm Ops & Technology
• Peter N Kellogg,
  Executive Vice President, CFO
• Mary L Good,
  Director
• Thomas F Keller,
  Director
• Connie Matsui,
  Sr V P, Planning& Resource Dev
• Christopher Viehbacher,
  President and CEO
• Maria C Freire,
  Director
• William D /Ca/ Jones,
  Director
• Nicole Murphy,
  Head of Pharm Ops and Tech
• Rachid Izzar,
  Head of Global Product Strat.
• Adam Keeney,
  Head of Corporate Development
• Jane Grogan,
  Head of Research